Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Lixivaptan

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Centessa Pharma To No Longer Develop Lixivaptan For Treatment Of ADPKD
    Centessa Pharma To No Longer Develop Lixivaptan For Treatment Of ADPKD

    03 Jun 2022

    // NASDAQ

    https://www.nasdaq.com/articles/centessa-pharma-to-no-longer-develop-lixivaptan-for-treatment-of-adpkd

    NASDAQ
    03 Jun 2022
    Share Share
    Palladio Biosciences Announces First Patient Dosed The ALERT Study
    Palladio Biosciences Announces First Patient Dosed The ALERT Study

    17 Nov 2020

    // BIOSPACE

    https://www.biospace.com/article/releases/palladio-biosciences-announces-first-patient-dosed-with-lixivaptan-in-the-alert-study-a-phase-3-study-of-adpkd-patients-previously-discontinued-from-treatment-with-tolvaptan-due-to-liver-toxicity/

    BIOSPACE
    17 Nov 2020
    Share Share
    Palladio Announces First Patient Dosed With Lixivaptan in The ALERT Study
    Palladio Announces First Patient Dosed With Lixivaptan in The ALERT Study

    17 Nov 2020

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20201117005255/en

    BUSINESSWIRE
    17 Nov 2020
    Share Share
    Palladio Biosciences Announces Presentation of Data from a Study of Lixivaptan
    Palladio Biosciences Announces Presentation of Data from a Study of Lixivaptan

    20 Oct 2020

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20201020005214/en/Palladio-Biosciences-Announces-Presentation-of-Data-from-a-Study-of-Lixivaptan-Use-in-an-ADPKD-Patient-who-Previously-Experienced-Liver-Toxicity-with-Tolvaptan-During-the-American-Society-of-Nephrology-Kidney-Week-2020-Meeting

    BUSINESSWIRE
    20 Oct 2020
    Share Share
    Palladio Completes $20 Million Series B Financing
    Palladio Completes $20 Million Series B Financing

    25 Sep 2020

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20200925005062/en

    BUSINESSWIRE
    25 Sep 2020
    Share Share
    Palladio Biosciences Announces ELiSA Ph 2 Study Results and Phase 3 Lixivaptan
    Palladio Biosciences Announces ELiSA Ph 2 Study Results and Phase 3 Lixivaptan

    05 Nov 2019

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20191105005459/en

    BUSINESSWIRE
    05 Nov 2019
    Share Share